Ignet
v2.0 Sign In

Gene Information

Gene symbol: WT1

Gene name: Wilms tumor 1

HGNC ID: 12796

Synonyms: WAGR, WIT-2, AWT1

Related Genes

# Gene Symbol Number of hits
1 CDKN1A 1 hits
2 CR1 1 hits
3 EGFR 1 hits
4 EGR2 1 hits
5 EGR3 1 hits
6 EGR4 1 hits
7 HGF 1 hits
8 MME 1 hits
9 NOV 1 hits
10 PAX2 1 hits
11 PTPRO 1 hits
12 RPL10 1 hits
13 SP1 1 hits
14 TP53 1 hits
15 WIT1 1 hits

Related Sentences

# PMID Sentence
1 8827074 The 11p13 Wilms' tumor locus consists of two coordinately regulated transcripts, WT1 and WIT-1.
2 8827074 The 11p13 Wilms' tumor locus consists of two coordinately regulated transcripts, WT1 and WIT-1.
3 8827074 The 11p13 Wilms' tumor locus consists of two coordinately regulated transcripts, WT1 and WIT-1.
4 8827074 The 11p13 Wilms' tumor locus consists of two coordinately regulated transcripts, WT1 and WIT-1.
5 8827074 WIT-1 mRNA is about 10-fold less abundant than WT1, but appears to be expressed in the same tissue-restricted manner.
6 8827074 WIT-1 mRNA is about 10-fold less abundant than WT1, but appears to be expressed in the same tissue-restricted manner.
7 8827074 WIT-1 mRNA is about 10-fold less abundant than WT1, but appears to be expressed in the same tissue-restricted manner.
8 8827074 WIT-1 mRNA is about 10-fold less abundant than WT1, but appears to be expressed in the same tissue-restricted manner.
9 8827074 The function of WIT-1 is similarly unknown but one intriguing possibility is that it is an antisense regulator of WT1.
10 8827074 The function of WIT-1 is similarly unknown but one intriguing possibility is that it is an antisense regulator of WT1.
11 8827074 The function of WIT-1 is similarly unknown but one intriguing possibility is that it is an antisense regulator of WT1.
12 8827074 The function of WIT-1 is similarly unknown but one intriguing possibility is that it is an antisense regulator of WT1.
13 8827074 An understanding of events controlling spatial and temporal regulation of these genes will greatly improve our ability to study the role of WT1 and WIT-1 in urogenital development.
14 8827074 An understanding of events controlling spatial and temporal regulation of these genes will greatly improve our ability to study the role of WT1 and WIT-1 in urogenital development.
15 8827074 An understanding of events controlling spatial and temporal regulation of these genes will greatly improve our ability to study the role of WT1 and WIT-1 in urogenital development.
16 8827074 An understanding of events controlling spatial and temporal regulation of these genes will greatly improve our ability to study the role of WT1 and WIT-1 in urogenital development.
17 9006935 Because Sp1 is important for WT1 expression, we examined Sp1 immunohistochemistry in fetal and adult kidney.
18 9006935 Because Sp1 is important for WT1 expression, we examined Sp1 immunohistochemistry in fetal and adult kidney.
19 9006935 Because Sp1 is important for WT1 expression, we examined Sp1 immunohistochemistry in fetal and adult kidney.
20 9006935 In a pattern that precedes that of WT1 message, Sp1 immunostaining was highest in uninduced mesenchyme, early tubules, developing podocytes, and mature glomeruli, but was minimal in mature proximal tubules.
21 9006935 In a pattern that precedes that of WT1 message, Sp1 immunostaining was highest in uninduced mesenchyme, early tubules, developing podocytes, and mature glomeruli, but was minimal in mature proximal tubules.
22 9006935 In a pattern that precedes that of WT1 message, Sp1 immunostaining was highest in uninduced mesenchyme, early tubules, developing podocytes, and mature glomeruli, but was minimal in mature proximal tubules.
23 9006935 This work suggests abundant Sp1 may be a prerequisite for WT1 expression, and that Sp1 may have a wider role in nephrogenesis.
24 9006935 This work suggests abundant Sp1 may be a prerequisite for WT1 expression, and that Sp1 may have a wider role in nephrogenesis.
25 9006935 This work suggests abundant Sp1 may be a prerequisite for WT1 expression, and that Sp1 may have a wider role in nephrogenesis.
26 9108440 Induction of p21 by the Wilms' tumor suppressor gene WT1.
27 9108440 Induction of p21 by the Wilms' tumor suppressor gene WT1.
28 9108440 Induction of p21 by the Wilms' tumor suppressor gene WT1.
29 9108440 Induction of p21 by the Wilms' tumor suppressor gene WT1.
30 9108440 Induction of p21 by the Wilms' tumor suppressor gene WT1.
31 9108440 Induction of p21 by the Wilms' tumor suppressor gene WT1.
32 9108440 Induction of p21 by the Wilms' tumor suppressor gene WT1.
33 9108440 We have recently shown that inducible expression of WT1 in osteosarcoma cells triggers programmed cell death, an effect that is associated with transcriptional repression of the endogenous epidermal growth factor receptor.
34 9108440 We have recently shown that inducible expression of WT1 in osteosarcoma cells triggers programmed cell death, an effect that is associated with transcriptional repression of the endogenous epidermal growth factor receptor.
35 9108440 We have recently shown that inducible expression of WT1 in osteosarcoma cells triggers programmed cell death, an effect that is associated with transcriptional repression of the endogenous epidermal growth factor receptor.
36 9108440 We have recently shown that inducible expression of WT1 in osteosarcoma cells triggers programmed cell death, an effect that is associated with transcriptional repression of the endogenous epidermal growth factor receptor.
37 9108440 We have recently shown that inducible expression of WT1 in osteosarcoma cells triggers programmed cell death, an effect that is associated with transcriptional repression of the endogenous epidermal growth factor receptor.
38 9108440 We have recently shown that inducible expression of WT1 in osteosarcoma cells triggers programmed cell death, an effect that is associated with transcriptional repression of the endogenous epidermal growth factor receptor.
39 9108440 We have recently shown that inducible expression of WT1 in osteosarcoma cells triggers programmed cell death, an effect that is associated with transcriptional repression of the endogenous epidermal growth factor receptor.
40 9108440 We now show that WT1-mediated apoptosis is preceded by induction of the cyclin-dependent kinase inhibitor p21, associated with G1 phase arrest.
41 9108440 We now show that WT1-mediated apoptosis is preceded by induction of the cyclin-dependent kinase inhibitor p21, associated with G1 phase arrest.
42 9108440 We now show that WT1-mediated apoptosis is preceded by induction of the cyclin-dependent kinase inhibitor p21, associated with G1 phase arrest.
43 9108440 We now show that WT1-mediated apoptosis is preceded by induction of the cyclin-dependent kinase inhibitor p21, associated with G1 phase arrest.
44 9108440 We now show that WT1-mediated apoptosis is preceded by induction of the cyclin-dependent kinase inhibitor p21, associated with G1 phase arrest.
45 9108440 We now show that WT1-mediated apoptosis is preceded by induction of the cyclin-dependent kinase inhibitor p21, associated with G1 phase arrest.
46 9108440 We now show that WT1-mediated apoptosis is preceded by induction of the cyclin-dependent kinase inhibitor p21, associated with G1 phase arrest.
47 9108440 This effect is only demonstrated by WT1 isoforms with an intact DNA binding domain, and it is associated with increased expression of endogenous p21 mRNA.
48 9108440 This effect is only demonstrated by WT1 isoforms with an intact DNA binding domain, and it is associated with increased expression of endogenous p21 mRNA.
49 9108440 This effect is only demonstrated by WT1 isoforms with an intact DNA binding domain, and it is associated with increased expression of endogenous p21 mRNA.
50 9108440 This effect is only demonstrated by WT1 isoforms with an intact DNA binding domain, and it is associated with increased expression of endogenous p21 mRNA.
51 9108440 This effect is only demonstrated by WT1 isoforms with an intact DNA binding domain, and it is associated with increased expression of endogenous p21 mRNA.
52 9108440 This effect is only demonstrated by WT1 isoforms with an intact DNA binding domain, and it is associated with increased expression of endogenous p21 mRNA.
53 9108440 This effect is only demonstrated by WT1 isoforms with an intact DNA binding domain, and it is associated with increased expression of endogenous p21 mRNA.
54 9108440 WT1-mediated induction of p21 is independent of p53, another tumor suppressor gene known to regulate p21 expression.
55 9108440 WT1-mediated induction of p21 is independent of p53, another tumor suppressor gene known to regulate p21 expression.
56 9108440 WT1-mediated induction of p21 is independent of p53, another tumor suppressor gene known to regulate p21 expression.
57 9108440 WT1-mediated induction of p21 is independent of p53, another tumor suppressor gene known to regulate p21 expression.
58 9108440 WT1-mediated induction of p21 is independent of p53, another tumor suppressor gene known to regulate p21 expression.
59 9108440 WT1-mediated induction of p21 is independent of p53, another tumor suppressor gene known to regulate p21 expression.
60 9108440 WT1-mediated induction of p21 is independent of p53, another tumor suppressor gene known to regulate p21 expression.
61 9108440 In the kidney, p21 is expressed in differentiating glomerular podocytes along with WT1.
62 9108440 In the kidney, p21 is expressed in differentiating glomerular podocytes along with WT1.
63 9108440 In the kidney, p21 is expressed in differentiating glomerular podocytes along with WT1.
64 9108440 In the kidney, p21 is expressed in differentiating glomerular podocytes along with WT1.
65 9108440 In the kidney, p21 is expressed in differentiating glomerular podocytes along with WT1.
66 9108440 In the kidney, p21 is expressed in differentiating glomerular podocytes along with WT1.
67 9108440 In the kidney, p21 is expressed in differentiating glomerular podocytes along with WT1.
68 9108440 We conclude that induction of p21 expression may contribute to WT1-dependent differentiation pathways in the kidney and potentially to the function of WT1 as a tumor suppressor gene.
69 9108440 We conclude that induction of p21 expression may contribute to WT1-dependent differentiation pathways in the kidney and potentially to the function of WT1 as a tumor suppressor gene.
70 9108440 We conclude that induction of p21 expression may contribute to WT1-dependent differentiation pathways in the kidney and potentially to the function of WT1 as a tumor suppressor gene.
71 9108440 We conclude that induction of p21 expression may contribute to WT1-dependent differentiation pathways in the kidney and potentially to the function of WT1 as a tumor suppressor gene.
72 9108440 We conclude that induction of p21 expression may contribute to WT1-dependent differentiation pathways in the kidney and potentially to the function of WT1 as a tumor suppressor gene.
73 9108440 We conclude that induction of p21 expression may contribute to WT1-dependent differentiation pathways in the kidney and potentially to the function of WT1 as a tumor suppressor gene.
74 9108440 We conclude that induction of p21 expression may contribute to WT1-dependent differentiation pathways in the kidney and potentially to the function of WT1 as a tumor suppressor gene.
75 9626060 We previously established that the expression of the human nov gene (novH) was altered in Wilms' tumors and that levels of novH and WT1 mRNA were inversely correlated in individual Wilms' tumors.
76 9626060 We previously established that the expression of the human nov gene (novH) was altered in Wilms' tumors and that levels of novH and WT1 mRNA were inversely correlated in individual Wilms' tumors.
77 9626060 We previously established that the expression of the human nov gene (novH) was altered in Wilms' tumors and that levels of novH and WT1 mRNA were inversely correlated in individual Wilms' tumors.
78 9626060 We previously established that the expression of the human nov gene (novH) was altered in Wilms' tumors and that levels of novH and WT1 mRNA were inversely correlated in individual Wilms' tumors.
79 9626060 Insofar as novH has been shown to be a target for WT1 regulation, novH might play an important role during normal nephrogenesis and in the development of Wilms' tumors.
80 9626060 Insofar as novH has been shown to be a target for WT1 regulation, novH might play an important role during normal nephrogenesis and in the development of Wilms' tumors.
81 9626060 Insofar as novH has been shown to be a target for WT1 regulation, novH might play an important role during normal nephrogenesis and in the development of Wilms' tumors.
82 9626060 Insofar as novH has been shown to be a target for WT1 regulation, novH might play an important role during normal nephrogenesis and in the development of Wilms' tumors.
83 9626060 In general, the highest novH expression was noted in the Wilms' tumor, genitourinary anomalies, aniridia, and mental retardation (WAGR)-associated Wilms' tumors.
84 9626060 In general, the highest novH expression was noted in the Wilms' tumor, genitourinary anomalies, aniridia, and mental retardation (WAGR)-associated Wilms' tumors.
85 9626060 In general, the highest novH expression was noted in the Wilms' tumor, genitourinary anomalies, aniridia, and mental retardation (WAGR)-associated Wilms' tumors.
86 9626060 In general, the highest novH expression was noted in the Wilms' tumor, genitourinary anomalies, aniridia, and mental retardation (WAGR)-associated Wilms' tumors.
87 9626060 In addition, absence or very low levels of WT1 are correlated with higher novH expression, and its variable expression in cases with mutant WT1 (sporadic and DDS) suggests that the potential activation and repression transcriptional functions possessed by WT1 are likely dependent on the specific mutation incurred.
88 9626060 In addition, absence or very low levels of WT1 are correlated with higher novH expression, and its variable expression in cases with mutant WT1 (sporadic and DDS) suggests that the potential activation and repression transcriptional functions possessed by WT1 are likely dependent on the specific mutation incurred.
89 9626060 In addition, absence or very low levels of WT1 are correlated with higher novH expression, and its variable expression in cases with mutant WT1 (sporadic and DDS) suggests that the potential activation and repression transcriptional functions possessed by WT1 are likely dependent on the specific mutation incurred.
90 9626060 In addition, absence or very low levels of WT1 are correlated with higher novH expression, and its variable expression in cases with mutant WT1 (sporadic and DDS) suggests that the potential activation and repression transcriptional functions possessed by WT1 are likely dependent on the specific mutation incurred.
91 9627060 Characterization of monoclonal antibodies directed to the amino-terminus of the WT1, Wilms' tumor suppressor protein.
92 9627060 Characterization of monoclonal antibodies directed to the amino-terminus of the WT1, Wilms' tumor suppressor protein.
93 9627060 Characterization of monoclonal antibodies directed to the amino-terminus of the WT1, Wilms' tumor suppressor protein.
94 9627060 We have produced and characterized three monoclonal antibodies (MAbs) directed to the amino terminus of the WT1 Wilms' tumor suppressor transcription factor and compared their properties to rabbit polyclonal sera raised to the same immunogen.
95 9627060 We have produced and characterized three monoclonal antibodies (MAbs) directed to the amino terminus of the WT1 Wilms' tumor suppressor transcription factor and compared their properties to rabbit polyclonal sera raised to the same immunogen.
96 9627060 We have produced and characterized three monoclonal antibodies (MAbs) directed to the amino terminus of the WT1 Wilms' tumor suppressor transcription factor and compared their properties to rabbit polyclonal sera raised to the same immunogen.
97 9627060 The WT1 antibodies do not recognize the structurally and functionally related early growth response (EGR)1, EGR2, EGR3, or EGR4 proteins.
98 9627060 The WT1 antibodies do not recognize the structurally and functionally related early growth response (EGR)1, EGR2, EGR3, or EGR4 proteins.
99 9627060 The WT1 antibodies do not recognize the structurally and functionally related early growth response (EGR)1, EGR2, EGR3, or EGR4 proteins.
100 9890309 The differentiation of podocytes coincides with progressive expression of maturity markers, including WT-1, CALLA, C3b receptor, GLEPP-1, podocalyxin, and synaptopodin.
101 9916932 WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis.
102 9916932 WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis.
103 9916932 WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis.
104 9916932 WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis.
105 9916932 WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis.
106 9916932 One target gene of WT1 is PAX2, the expression of which is down-regulated in podocytes during early stages of nephrogenesis.
107 9916932 One target gene of WT1 is PAX2, the expression of which is down-regulated in podocytes during early stages of nephrogenesis.
108 9916932 One target gene of WT1 is PAX2, the expression of which is down-regulated in podocytes during early stages of nephrogenesis.
109 9916932 One target gene of WT1 is PAX2, the expression of which is down-regulated in podocytes during early stages of nephrogenesis.
110 9916932 One target gene of WT1 is PAX2, the expression of which is down-regulated in podocytes during early stages of nephrogenesis.
111 9916932 We demonstrate that WT1 mislocalization is associated with abnormal podocyte expression of PAX2 protein and RNA.
112 9916932 We demonstrate that WT1 mislocalization is associated with abnormal podocyte expression of PAX2 protein and RNA.
113 9916932 We demonstrate that WT1 mislocalization is associated with abnormal podocyte expression of PAX2 protein and RNA.
114 9916932 We demonstrate that WT1 mislocalization is associated with abnormal podocyte expression of PAX2 protein and RNA.
115 9916932 We demonstrate that WT1 mislocalization is associated with abnormal podocyte expression of PAX2 protein and RNA.
116 9916932 We suggest that persistent expression of PAX2 is likely to result from the loss of WT1 dependent transcriptional repression and may participate in the pathological mechanisms leading to glomerular dysfunction.
117 9916932 We suggest that persistent expression of PAX2 is likely to result from the loss of WT1 dependent transcriptional repression and may participate in the pathological mechanisms leading to glomerular dysfunction.
118 9916932 We suggest that persistent expression of PAX2 is likely to result from the loss of WT1 dependent transcriptional repression and may participate in the pathological mechanisms leading to glomerular dysfunction.
119 9916932 We suggest that persistent expression of PAX2 is likely to result from the loss of WT1 dependent transcriptional repression and may participate in the pathological mechanisms leading to glomerular dysfunction.
120 9916932 We suggest that persistent expression of PAX2 is likely to result from the loss of WT1 dependent transcriptional repression and may participate in the pathological mechanisms leading to glomerular dysfunction.
121 9916932 Abnormal distribution of WT1 and PAX2 was also observed in isolated diffuse mesangial sclerosis suggesting that a defect in WT1 could also be operative in isolated diffuse mesangial sclerosis.
122 9916932 Abnormal distribution of WT1 and PAX2 was also observed in isolated diffuse mesangial sclerosis suggesting that a defect in WT1 could also be operative in isolated diffuse mesangial sclerosis.
123 9916932 Abnormal distribution of WT1 and PAX2 was also observed in isolated diffuse mesangial sclerosis suggesting that a defect in WT1 could also be operative in isolated diffuse mesangial sclerosis.
124 9916932 Abnormal distribution of WT1 and PAX2 was also observed in isolated diffuse mesangial sclerosis suggesting that a defect in WT1 could also be operative in isolated diffuse mesangial sclerosis.
125 9916932 Abnormal distribution of WT1 and PAX2 was also observed in isolated diffuse mesangial sclerosis suggesting that a defect in WT1 could also be operative in isolated diffuse mesangial sclerosis.
126 10456263 In addition, study of the Wilms' tumor suppressor, WT1, is revealing much about the pathogenesis of Wilms' tumor, urogenital development, and glomerular podocyte biology. c-met, the gene encoding the hepatocyte growth factor receptor, has recently been identified as a causative gene for hereditary papillary renal cancer.